Daniel J. Wallace

42.4k citations
294 papers · 16.5k · 8 hit papers · h-index 63

Impact in

  • Rheumatology top 0.01%
    • Systemic Lupus Erythematosus Research
    • Rheumatoid Arthritis Research and Therapies
  • Immunology top 0.1%
    • T-cell and B-cell Immunology
    • Atherosclerosis and Cardiovascular Diseases
    • Immune Cell Function and Interaction

Papers in

    • Systemic Lupus Erythematosus Research 172
    • Rheumatoid Arthritis Research and Therapies 16
    • T-cell and B-cell Immunology 17

Daniel J. Wallace

282 papers receiving 15.9k citations

Daniel J. Wallace's Hit Papers

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) 2023 · 89 citations
890+12+25Years since publication2505007501000

Peers

Daniel J. Wallace
Comparison fields: 5 of 165
  • Rheumatology 10.7k
  • Immunology 6.3k
  • Radiology, Nuclear Medicine and Imaging 3.4k
  • Nephrology 966
  • Hepatology 585
Replace Caroline Gordon with:
Caroline Gordon United Kingdom
Andrea Doria Italy
Michelle Petri United States
Naomi F. Rothfield United States
John D. Reveille United States
Ronald van Vollenhoven Sweden
Eric L. Matteson United States
Graciela S. Alarcón United States
Guido Valesini Italy
Dennis J. McShane United States
Daniel J. Wallace relative to Caroline Gordon United Kingdom Caroline Gordon's profile →
Citations per field
00.5×1.5×
Caroline Gordon · 1×
Citations per year

Countries citing papers authored by Daniel J. Wallace

Since Specialization
Citations

This map shows the geographic impact of Daniel J. Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Wallace more than expected).

Fields of papers citing papers by Daniel J. Wallace

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Wallace. The network helps show where Daniel J. Wallace may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel J. Wallace, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel J. Wallace Line = papers co-authored together Daniel J. Wallace links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 294 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Hit paper breakdown →
20111166
2
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Hit paper breakdown →
2009984
3
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Hit paper breakdown →
2005770
4
Dubois' Lupus Erythematosus
Hit paper breakdown →
1988561
5
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
Hit paper breakdown →
2005500
6 2003461
7 1991444
8
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
Hit paper breakdown →
2009412
9
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Hit paper breakdown →
2018364
10 2009345
11 2006327
12 2010278
13 2013254
14 2001253
15 2007248
16 1981210
17 1997201
18 2006201
19 2013200
20 2015182

About Daniel J. Wallace

Daniel J. Wallace is a scholar working on Rheumatology, Immunology, Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Physiology, having authored 294 papers that have together received 16.5k indexed citations. Recurring topics across this work include Systemic Lupus Erythematosus Research (172 papers), Monoclonal and Polyclonal Antibodies Research (26 papers), T-cell and B-cell Immunology (17 papers), Rheumatoid Arthritis Research and Therapies (16 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (14 papers), Autoimmune and Inflammatory Disorders Research (10 papers), Renal Diseases and Glomerulopathies (10 papers) and Systemic Sclerosis and Related Diseases (9 papers). The work is most often cited by research in Rheumatology (10.7k citations), Immunology (6.3k citations), Radiology, Nuclear Medicine and Imaging (3.4k citations), Nephrology (966 citations) and Hepatology (585 citations). Daniel J. Wallace has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Michael H. Weisman, Joan T. Merrill, Michelle Petri, Richard Furie, Ellen M. Ginzler, James R. Klinenberg, Mariana Linker‐Israeli, Kenneth Kalunian, David Isenberg and William Stohl. Their work appears in journals such as Lupus, Annals of the Rheumatic Diseases, Seminars in Arthritis and Rheumatism, Arthritis & Rheumatology and Lupus Science & Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact